ARHGEF37 Activators
ARHGEF37 activators boost the signaling pathways that control RhoA, a GTPase enzyme, by directly stimulating the enzymes that create second messengers. These activators help release RhoA from its exchange factors, making it easier for RhoA to swap GDP for GTP and thus increasing ARHGEF37's activity. Certain kinases also play a role by adding phosphate groups to exchange factors, which might increase ARHGEF37's ability to swap nucleotides. GTP analogs that don't easily break down are used to keep Rho GTPase active for longer, improving ARHGEF37's function. Additionally, signals from ligand-receptor interactions can indirectly make the downstream Rho GTPase signaling stronger, which in turn boosts ARHGEF37's effectiveness.
At the same time, inhibitors that block the phosphorylation of certain negative regulators in the Rho GTPase signaling process can make ARHGEF37 better at loading RhoA with GTP. Blocking certain enzymes can also trigger other pathways that affect Rho GTPase regulation, creating a better situation for ARHGEF37 to work effectively. Molecules that stop the prenylation and membrane attachment of RhoA can increase the chances of cytosolic interactions that improve ARHGEF37's ability to activate RhoA. Other activators work by affecting cell surface receptors, which leads to enhanced RhoA signaling and indirectly increases ARHGEF37's activity, ensuring a steady supply of active GTP-bound RhoA.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Activates protein kinase C (PKC) which can phosphorylate and regulate guanine nucleotide exchange factors such as ARHGEF37, potentially increasing its exchange activity. | ||||||
Guanosine 5′-O-(3-thiotriphosphate) tetralithium salt | 94825-44-2 | sc-202639 | 10 mg | $465.00 | ||
Non-hydrolyzable GTP analog, directly binds and activates Rho GTPases, thereby potentially enhancing ARHGEF37-mediated exchange through substrate cycling. | ||||||
Calpeptin | 117591-20-5 | sc-202516 sc-202516A | 10 mg 50 mg | $121.00 $456.00 | 28 | |
Inhibitor of calpain which, when active, can cleave and inactivate Rho GTPase-activating proteins (GAPs), indirectly leading to increased activity of ARHGEF37 by reducing its inhibition. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
ROCK inhibitor that can lead to reduced phosphorylation and inhibition of RhoA, potentiating the activity of ARHGEF37 by allowing more GTP loading on RhoA. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Inhibits GSK-3β, resulting in the activation of the Wnt signaling pathway which can indirectly upregulate ARHGEF37 activity by modulating Rho GTPases. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
Inhibits Rac1-specific guanine nucleotide exchange factors, shifting the balance of Rho GTPase signaling towards RhoA, potentially enhancing ARHGEF37's specificity towards RhoA. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
A specific inhibitor of Cdc42 which can lead to compensatory upregulation of RhoA signaling, indirectly increasing the activity of ARHGEF37. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Inhibits HMG-CoA reductase, decreasing prenylation and membrane localization of RhoA, which may enhance cytosolic interactions with ARHGEF37, leading to increased activation of RhoA. | ||||||
Lysophosphatidic Acid | 325465-93-8 | sc-201053 sc-201053A | 5 mg 25 mg | $98.00 $341.00 | 50 | |
Binds to its G-protein-coupled receptors and activates RhoA signaling, which can indirectly enhance ARHGEF37 activity by increasing the pool of GTP-bound RhoA. | ||||||